---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022593"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T06:22:19.742150+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q3 loss of $91.7M; China roxadustat revenue up 29% YoY to $17.4M

## Summary
- Total revenue $15.7M vs $156.0M in Q3 2021, which included $120M Astellas milestone
- Net loss $91.7M ($0.98/sh) vs net income $49.8M ($0.54/sh) year ago
- China roxadustat net sales $59.0M (incl. JDE); volume growth >80% vs Q3 2021
- Completed MATTERHORN Phase 3 enrollment; topline data expected 1H 2023
- Non-dilutive royalty monetization with NovaQuest provides $50M; cash target $380-410M YE 2022

## SEC filing metadata
- accession: 0000950170-22-022593
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017022022593/0000950170-22-022593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017022022593/fgen-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022593
- JSON: https://secwatch.observer/filing/0000950170-22-022593.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022593.txt

## Key facts
- Earnings Releases
  KYNTRA BIO, INC. reported the third quarter 2022 results: revenue $15.7 million, net income Net loss for the third quarter of 2022 was $91.7 million, or $0.98 net loss per basic and diluted share, EPS $0.98 net loss per basic and diluted share.
  - Period: the third quarter 2022
  - Revenue: $15.7 million
  - Net income: Net loss for the third quarter of 2022 was $91.7 million, or $0.98 net loss per basic and diluted share
  - EPS: $0.98 net loss per basic and diluted share
  - Result: reported results
  source text: Total revenue for the third quarter of 2022 was $15.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017022022593/0000950170-22-022593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.